Literature DB >> 31807307

Endoscopic measurement of gastric pH associates with persistent acid reflux in patients treated with proton-pump inhibitors for gastroesophageal reflux disease.

Wladyslaw Januszewicz1,2, James Hartley1, William Waldock1, Geoffrey Roberts1, Bincy Alias1, Anthony Hobson3, Lorenz Wernisch4, Massimiliano di Pietro1.   

Abstract

Background: Proton-pump inhibitors (PPIs) are the mainstay of gastroesophageal reflux disease (GERD) treatment, however, up to 30% of patients have a poor symptomatic response. PH-impedance is the gold standard to assess whether this is due to persistent acid reflux. We aimed to characterize clinical predictors of persistent esophageal acid reflux on PPIs including gastric pH measured during endoscopy.
Methods: We prospectively recruited patients with GERD and/or Barrett's esophagus (BE) on PPIs. All patients completed a symptom questionnaire (RDQ) and underwent gastroscopy with gastric pH analysis, immediately followed by ambulatory 24-hour pH-impedance. We used a modified cut-off of 1.3% for pathological esophageal acid exposure time (AET). Multiple linear regression model was used to analyze the correlation between AET and predictive variables.
Results: We recruited 122 patients, of which 92 (75.4%) were included in the final analysis [44 male (47.8%), median age 53 years (IQR: 43-66)]. Forty-four patients (47.8%) had persistent acid reflux with a median total AET of 2.2 (IQR1.2-5.0), as compared to 0.1 (IQR 0.0-0.2) in patients without persistent reflux (n=48; P<.001). There was no difference in age, gender, BMI, PPI-regimen, diagnosis of hiatus hernia or BE, and severity of symptoms between patients with normal and abnormal AET. Median gastric pH was significantly lower in patients with abnormal AET (5.8 vs 6.6, P=0.032) and it correlated with the total AET (P=.045; R2=12.0%). With a pH cut-off of 5.05, single point endoscopic gastric pH analysis had an area under the ROC curve (AUC) of 63.0% (95%CI 51.3-74.7) for prediction of pathological esophageal AET. Conclusions: Symptoms and clinical characteristics are not useful to predict persistent acid reflux in patients on PPIs. One-point gastric pH correlates with 24-hour esophageal AET and could guide clinicians to assess response to PPIs, however, its utility needs validation in larger studies.

Entities:  

Keywords:  Barrett Esophagus; Esophagitis; Esophagus; Gastroesophageal Reflux

Mesh:

Substances:

Year:  2019        PMID: 31807307      PMCID: PMC6894008          DOI: 10.1177/2050640619880362

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  17 in total

1.  The endoscopic assessment of esophagitis: a progress report on observer agreement.

Authors:  D Armstrong; J R Bennett; A L Blum; J Dent; F T De Dombal; J P Galmiche; L Lundell; M Margulies; J E Richter; S J Spechler; G N Tytgat; L Wallin
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

2.  The patient with refractory gastroesophageal reflux disease.

Authors:  J E Richter
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

Review 3.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

Review 4.  Proton-pump inhibitors: understanding the complications and risks.

Authors:  Peter Malfertheiner; Arne Kandulski; Marino Venerito
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

5.  The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Authors:  Nimish Vakil; Sander V van Zanten; Peter Kahrilas; John Dent; Roger Jones
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

6.  Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.

Authors:  John Dent; Nimish Vakil; Roger Jones; Peter Bytzer; Uwe Schöning; Katarina Halling; Ola Junghard; Tore Lind
Journal:  Gut       Date:  2010-06       Impact factor: 23.059

Review 7.  Effectiveness of proton pump inhibitors in nonerosive reflux disease.

Authors:  Bonnie B Dean; Anacleto D Gano; Kevin Knight; Joshua J Ofman; Ronnie Fass
Journal:  Clin Gastroenterol Hepatol       Date:  2004-08       Impact factor: 11.382

8.  Perendoscopic real-time assessment of pH improves detection of gastric preneoplastic conditions.

Authors:  G Pezzicoli; F A Tucci; A Ummarino; P Tucci; A P Di Virgilio; M Bisceglia; M Rugge; A Tucci; A Andriulli
Journal:  Minerva Gastroenterol Dietol       Date:  2013-03

9.  Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.

Authors:  Abeezar I Sarela; David G Hick; Caroline S Verbeke; John F Casey; Pierre J Guillou; Geoffrey W B Clark
Journal:  Arch Surg       Date:  2004-05

10.  High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease--a prospective pH-metry/impedance-controlled study.

Authors:  Monther Bajbouj; Valentin Becker; Veit Phillip; Dirk Wilhelm; Roland M Schmid; Alexander Meining
Journal:  Digestion       Date:  2009-07-27       Impact factor: 3.216

View more
  1 in total

1.  UEGWeek: The modern School of Athens.

Authors:  Livia Archibugi
Journal:  United European Gastroenterol J       Date:  2021-09       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.